Welcome to our dedicated page for VSee Health SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. filed a prospectus supplement registering for resale up to 33,808,195 shares of Common Stock by named selling stockholders, including 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares, 9,836,065 pre-funded warrant shares and 19,672,130 warrant shares. The supplement incorporates Form 8-K disclosure of a Standby Equity Purchase Agreement dated June 2, 2026 under which YA II PN, LTD. commits up to $10,000,000 in purchase capacity through June 2, 2029, subject to a Nasdaq Exchange Cap of 9,715,140 shares (approximately 19.99%) and an ownership limit of 4.99%. Pricing under the SEPA is set at 97% of the lowest daily VWAP during a three-consecutive trading day Pricing Period. The prospectus supplement and Prospectus govern resale mechanics; proceeds treatment is for selling stockholders.
VSee Health, Inc. entered into a high-interest note financing with an institutional investor. The company issued an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, which includes an original issue discount of $21,739.13. The note bears interest at 18% per annum and matures on December 8, 2026.
The company may prepay all or part of the note at 100% of the amount redeemed plus a 10% prepayment fee. If VSee receives proceeds from an equity line of credit with the same holder, it must repay the entire outstanding balance within two business days. The note is secured by certain company assets under a related security agreement.
VSee Health, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., giving the company the right to sell up to $10 million of common stock over time. The arrangement runs until June 2, 2029, unless the full commitment is used or it is terminated earlier.
Shares sold under each Advance will be priced at 97% of the lowest daily VWAP over a three-day pricing period. VSee will issue 532,481 commitment shares and pay a $25,000 structuring fee from the first Advance. Issuances are capped at 9,715,140 shares, about 19.99% of pre-agreement outstanding shares, and the investor’s beneficial ownership is limited to 4.99%.
VSee Health, Inc. filed a prospectus supplement registering the resale of up to 33,808,195 shares of Common Stock.
The supplement breaks that aggregate into 3,000,000 Manatt Shares; up to 1,300,000 Series B Shares; 9,836,065 pre-funded warrant shares; and 19,672,130 warrant shares. The supplement attaches a Form 8-K describing the sale of VSee Lab to Milton Chen, who agreed to transfer 2,870,069 shares of Common Stock back to the company and resigned as co-CEO and chair; Dr. Imoigele Aisiku is now sole CEO and chair. The common stock last reported at $0.1570 per share on Nasdaq on June 9, 2026.
VSee Health, Inc. agreed to sell all of the equity of its wholly owned subsidiary VSee Lab, Inc. to co-Chief Executive Officer and Chairman Milton Chen, effective May 31, 2026. In return, Chen will transfer to the company all 2,870,069 shares of VSee Health common stock he owns, which are treated as a stock repurchase.
Under the agreement, Chen is solely responsible for indebtedness and other liabilities of VSee Lab not paid at closing, while VSee Health remains responsible for liabilities tied to periods on or before the closing date, including most taxes. Concurrent with closing, Chen resigned as co-Chief Executive Officer and chairman; co-CEO Dr. Imoigele Aisiku became sole Chief Executive Officer and chairman.
Unaudited pro forma financials show how results would look without VSee Lab and its subsidiary. For 2025, revenue would decline from $14,618,184 to $7,302,954, while net loss would narrow from $14,712,850 to $9,972,749. For the quarter ended March 31, 2026, revenue would fall from $3,160,185 to $1,879,293 and net loss would narrow from $2,600,262 to $1,264,882.
VSee Health, Inc. director and Co-Chief Executive Officer Milton Chen reported an internal restructuring transaction. On May 31, 2026, he transferred 2,870,069 shares of Common Stock to VSee Health, Inc. as consideration under a Stock Purchase Agreement related to his purchase of all equity securities of VSee Lab, Inc. from the company. Following this transaction, his directly held VSee common stock position was reported as 0 shares.
VSee Health, Inc. registers for resale up to 33,808,195 shares of common stock for named selling stockholders, including shares issuable upon conversion of Series B preferred stock, warrants and pre-funded warrants. This prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The supplement covers resale by Manatt and Armistice from private placements and attaches updated financials showing cash of $1,346,132, an accumulated deficit of $85,016,985, and a reported net loss of $2,600,262 for Q1 2026. Management discloses substantial doubt about going concern for at least one year and lists measures being undertaken to address liquidity.
VSee Health, Inc. reported first‑quarter 2026 revenue of $3.16 million, compared with $3.32 million in the prior‑year quarter. Gross margin was $1.20 million while operating expenses rose to $4.17 million, leading to a net operating loss of $2.97 million.
Net loss narrowed to $2.60 million versus $3.96 million a year earlier, helped by a $367,809 gain on extinguishment of financial liabilities and a $143,040 gain from changes in fair value of financial instruments. Basic and diluted loss per share was $0.05 on a weighted average of 47.9 million shares.
Cash declined to $1.35 million from $5.27 million at December 31, 2025, with operating activities using $2.45 million of cash in the quarter. The company ended the period with total assets of $19.0 million, liabilities of $12.7 million, and stockholders’ equity of $6.32 million, alongside an accumulated deficit of $85.0 million. Management states that recurring losses and liquidity conditions raise substantial doubt about VSee Health’s ability to continue as a going concern.
VSee Health, Inc. Schedule 13G/A reports that Armistice Capital, LLC and Steven Boyd together beneficially own 4,861,392 shares, representing 9.99% of the outstanding common stock. The filing states Armistice Capital shares voting and dispositive power over those shares through its role as investment manager of Armistice Capital Master Fund Ltd.
The statement explains the Master Fund is the direct holder and that the Master Fund "specifically disclaims beneficial ownership" by reason of its inability to vote or dispose under its Investment Management Agreement. The amendment is signed by Steven Boyd on 05/15/2026.
VSee Health, Inc. registers 33,808,195 shares of Common Stock for resale by the named selling stockholders.
The registration consists of 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares issuable upon conversion, 9,836,065 pre-funded warrant shares and 19,672,130 warrant shares. Shares outstanding were 47,299,421 as of March 30, 2026. The supplement incorporates the Form 10-K for the fiscal year ended December 31, 2025 and updates the prospectus; resale activity is by the selling stockholders.